SCHEMBL352427

SCHEMBL352427

Cc1nn(C)c(Cl)c1C(=O)N(C)Cc1nsc(NC(=O)NCc2ccc(Cl)s2)n1

nearest known ligand 0.35

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.35
RAB9A P51151 5/20 0.34
KMT2A Q03164 5/20 0.34
ALDH1A1 P00352 5/20 0.34
NPC1 O15118 2/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
LMNA P02545 2/20 0.33
HTT P42858 1/20 0.33
GPBAR1 Q8TDU6 1/20 0.31
MEN1 O00255 2/20 0.31
NPSR1 Q6W5P4 1/20 0.31
KDM4E B2RXH2 1/20 0.31
FPR3 P25089 1/20 0.30
FPR2 P25090 1/20 0.30
POLB P06746 1/20 0.30
HPGD P15428 1/20 0.30
RECQL P46063 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19119282 0.87 RAB9A (0.33) SMN1; SMN2RAB9AKMT2AALDH1A1NPC1
SCHEMBL352961 0.86 KMT2A (0.37) SMN1; SMN2RAB9AKMT2AALDH1A1NPC1
SCHEMBL354377 0.84 ALDH1A1 (0.32) SMN1; SMN2RAB9AKMT2AALDH1A1NPC1
SCHEMBL352957 0.83 ROCK2 (0.43) SMN1; SMN2RAB9ANPC1GPBAR1
SCHEMBL353808 0.82 TRPA1 (0.34) SMN1; SMN2RAB9AKMT2AALDH1A1HTT
SCHEMBL353858 0.81 HTT (0.42) SMN1; SMN2RAB9AKMT2AALDH1A1LMNA
SCHEMBL352384 0.81 ALDH1A1 (0.37) SMN1; SMN2KMT2AALDH1A1L3MBTL1LMNA
SCHEMBL353121 0.80 ATG4B (0.36) SMN1; SMN2RAB9AKMT2AALDH1A1NPC1
SCHEMBL19119086 0.80 SHMT2 (0.31) SMN1; SMN2RAB9AKMT2AALDH1A1NPC1
SCHEMBL353525 0.80 RAB9A (0.38) SMN1; SMN2RAB9AKMT2AALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8148380-B2 Antibacterial amide and sulfonamide substituted heterocyclic urea compounds CRESTONE, INC. (US) 2012-04-03 US claimed
US-20120015941-A1 Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds CRESTONE, INC. (US) 2012-01-19 US claimed
US-8148380-B2 Antibacterial amide and sulfonamide substituted heterocyclic urea compounds CRESTONE, INC. (US) 2012-04-03 US disclosed
US-20120015941-A1 Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds CRESTONE, INC. (US) 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015941-A1 Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds NAAA, AADAC, RPSA SMN1; SMN2 2356/4885RAB9A 1714/4885KMT2A 1210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.